Understanding the functional role of Immune-related Intercellular Signalling Networks during tissue Development and Cancer

This project aims to uncover immune-related intercellular crosstalk in tissue development and cancer using single-cell RNA-sequencing and functional assays to identify novel therapeutic targets.

Subsidie
€ 2.025.000
2022

Projectdetails

Introduction

Intercellular signalling networks drive fundamental tissue processes. Immune cells present a wide range of versatile functions and distinctive plasticity, which position them as tissue signalling hubs during tissue development, homeostasis, and cancer. Recent genomic advances have greatly improved our understanding of cell composition and states; however, investigation of the molecular signatures of intercellular crosstalk at the single-cell level remains limited.

Research Objectives

Exploring tissue development, homeostasis, and cancer from the point of view of immune-controlled signalling networks has the potential to reveal novel therapeutic candidates with high biological and medical impact. By applying functional assays alongside novel single-cell RNA-sequencing technologies and computational approaches, such as physically interacting-cell sequencing (PIC-seq), I propose to crack the functional consequences of the whole-tissue signalling networks to revisit key developmental and cancer immunology questions:

  1. What immune-related intercellular crosstalk drives tissue development and cancer?
    We will integrate scRNA-seq and PIC-seq analysis along mouse lung, liver, and kidney development, and human carcinomas. We will apply large-scale comparative cross-tissue and cross-species analysis, ex-vivo and in-vivo studies, to identify tissue-exclusive and shared signalling during tissue physiology or cancer.

  2. What can we study on tumor-escape mechanisms, based on physiological signalling networks?
    We will perform development versus cancer large-scale molecular comparisons, in-vivo cancer models for functional perturbations, and clinical validations to identify novel immunotherapy targets.

Expected Outcomes

Successful completion of the project will reveal novel cancer and developmental immunotherapy targets. Concomitantly, findings will comprise a valuable resource for tissue-molecular signalling and will generate a platform for investigating biological enigmas by elucidating the consequences of cellular communication.

Financiële details & Tijdlijn

Financiële details

Subsidiebedrag€ 2.025.000
Totale projectbegroting€ 2.025.000

Tijdlijn

Startdatum1-4-2022
Einddatum31-3-2027
Subsidiejaar2022

Partners & Locaties

Projectpartners

  • TEL AVIV UNIVERSITYpenvoerder

Land(en)

Israel

Vergelijkbare projecten binnen European Research Council

ERC Starting...

Elucidating the networks of immune stromal connections by Perturbation of Immunity in Cancer - towards developing novel therapeutic strategies

This project aims to map immune and stromal cell interactions in the tumor microenvironment to develop targeted therapies that enhance immunotherapy efficacy against cancer.

€ 1.500.000
ERC Advanced...

Architecture of Peripheral Neuroimmune Circuits and Synapses

This project aims to explore neuro-ILC2 interactions in vivo using innovative labelling tools to enhance understanding of neuroimmune dynamics and their implications for tissue health and disease.

€ 3.500.000
ERC Advanced...

Developing novel single-cell technologies to model and perturb intra-tumor interactions and signaling – an innovation program for the next generation of immunotherapies

The TROJAN-Cell project aims to engineer immune responses against tumors by understanding immune-suppressive mechanisms in the tumor microenvironment using advanced single-cell technologies.

€ 2.500.000
ERC Starting...

Spatial Quantification of Cellular Metabolism in the Tumor Immune Microenvironment

This project aims to enhance cancer immunotherapy by quantifying immune cell metabolism in tumors to identify therapeutic targets that improve patient responses to treatment.

€ 1.497.756
ERC Consolid...

Integrated Mechanistic Modelling and Analysis of Large-scale Biomedical Data

INTEGRATE aims to enhance cancer treatment by developing advanced computational models that integrate patient-derived data for improved drug targeting and clinical trial planning.

€ 1.854.546